Priorix®

BIOLOGICAL2 trials

Sponsors

GlaxoSmithKline, Themis Bioscience GmbH

Conditions

Chikungunya Virus InfectionMeaslesMumpsRubella

Phase 2

Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine

CompletedNCT02861586

Themis Bioscience GmbHChikungunya Virus Infection

Start: 2016-08-17End: 2018-04-16Updated: 2021-10-29

Phase 3

Immunogenicity and Safety of GSK Biologicals' Combined Measles-mumps-rubella Vaccine in Volunteers, Seven Years of Age and Older

CompletedNCT02058563

GlaxoSmithKlineMeasles, Mumps, Rubella

Start: 2014-07-01End: 2015-09-17Updated: 2018-06-06

Related Papers

Phase 2 clinical results: Chikungunya vaccine based on measles vector (MV-CHIK) induces humoral and cellular responses in the presence of pre-existing anti measles immunity

International Journal of Infectious Diseases2019-01-304 citations

Immunogenicity, safety, and tolerability of the measles-vectored chikungunya virus vaccine MV-CHIK: a double-blind, randomised, placebo-controlled and active-controlled phase 2 trial.

2018-11-05117 citations

Immunogenicity and safety of a second dose of a measles-mumps-rubella vaccine administered to healthy participants 7 years of age or older: A phase III, randomized study

Human Vaccines & Immunotherapeutics2018-06-1437 citations